These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29248596)

  • 1. The wonderland of neuronal nicotinic acetylcholine receptors.
    Bertrand D; Terry AV
    Biochem Pharmacol; 2018 May; 151():214-225. PubMed ID: 29248596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease.
    Haydar SN; Dunlop J
    Curr Top Med Chem; 2010; 10(2):144-52. PubMed ID: 20166959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies.
    Pandya AA; Yakel JL
    Biochem Pharmacol; 2013 Oct; 86(8):1054-62. PubMed ID: 23732296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric modulation of nicotinic acetylcholine receptors.
    Chatzidaki A; Millar NS
    Biochem Pharmacol; 2015 Oct; 97(4):408-417. PubMed ID: 26231943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
    Verma S; Kumar A; Tripathi T; Kumar A
    J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotinic acetylcholine receptors as drug targets.
    Hogg RC; Bertrand D
    Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):123-30. PubMed ID: 15078187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators.
    Wilkerson JL; Deba F; Crowley ML; Hamouda AK; McMahon LR
    Neuropharmacology; 2020 May; 168():108008. PubMed ID: 32113032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing selective modulators for the nicotinic receptor subtypes: challenges and opportunities.
    Manetti D; Bellucci C; Chiaramonte N; Dei S; Teodori E; Romanelli MN
    Future Med Chem; 2018 Feb; 10(4):433-459. PubMed ID: 29451400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical and virtual screening methods for marine toxins and drug discovery targeting nicotinic acetylcholine receptors.
    Molgó J; Aráoz R; Benoit E; Iorga BI
    Expert Opin Drug Discov; 2013 Oct; 8(10):1203-23. PubMed ID: 23919818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors.
    Pandya A; Yakel JL
    Biochem Pharmacol; 2011 Oct; 82(8):952-8. PubMed ID: 21596025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo neuronal nicotinic receptor properties of (+)- and (-)-pyrido[3,4]homotropane [(+)- and (-)-PHT]: (+)-PHT is a potent and selective full agonist at α6β2 containing neuronal nicotinic acetylcholine receptors.
    Carroll FI; Navarro HA; Mascarella SW; Castro AH; Luetje CW; Wageman CR; Marks MJ; Jackson A; Damaj MI
    ACS Chem Neurosci; 2015 Jun; 6(6):920-6. PubMed ID: 25891987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists.
    Jonnala RR; Buccafusco JJ
    J Neurosci Res; 2001 Nov; 66(4):565-72. PubMed ID: 11746376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotinic Acetylcholine Receptor Ligands, Cognitive Function, and Preclinical Approaches to Drug Discovery.
    Terry AV; Callahan PM
    Nicotine Tob Res; 2019 Feb; 21(3):383-394. PubMed ID: 30137518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors.
    Hogg RC; Bertrand D
    Biochem Pharmacol; 2007 Feb; 73(4):459-68. PubMed ID: 16979139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotinic Acetylcholine Receptors in the Pathophysiology of Al zheimer's Disease: The Role of Protein-Protein Interactions in Current and Future Treatment.
    Thomsen MS; Andreasen JT; Arvaniti M; Kohlmeier KA
    Curr Pharm Des; 2016; 22(14):2015-34. PubMed ID: 26818866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia.
    Ishikawa M; Hashimoto K
    Curr Pharm Des; 2011; 17(2):121-9. PubMed ID: 21355839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and development of α7 nicotinic acetylcholine receptor modulators.
    Mazurov AA; Speake JD; Yohannes D
    J Med Chem; 2011 Dec; 54(23):7943-61. PubMed ID: 21919481
    [No Abstract]   [Full Text] [Related]  

  • 18. Nicotinic receptors, allosteric proteins and medicine.
    Changeux JP; Taly A
    Trends Mol Med; 2008 Mar; 14(3):93-102. PubMed ID: 18262468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.
    Potasiewicz A; Nikiforuk A; Hołuj M; Popik P
    J Psychopharmacol; 2017 Feb; 31(2):260-271. PubMed ID: 28168926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.
    Grupe M; Grunnet M; Bastlund JF; Jensen AA
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):187-200. PubMed ID: 25441336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.